Home / Analysis / Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
Schroder Global Healthcare and Axa Framlinton Health Care have returned 519% and 289% over the past decade
The biotech and healthcare sectors have flourished during the pandemic as companies raced to develop a Covid-19 vaccine. Those already invested have reaped the rewards, but what next? Is it time to reconsider this exposure or is there more to come?
Data from Grand View Research forecasts the biotech market to grow from $752.88bn in 2020 to $2.44trn by 2028. Similarly, genomics is expected to reach $62.9bn by 2028 driven by healthcare innovation and tailoring care to an individual patient, while providing more data on diseases and human genetics.
Merck Celebrates Key Milestone in Construction of Biotech Development Center in Switzerland finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DiscovOre Plc - Conditional Subscription with Angelfish Investments plc PR Newswire London, June 11 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY